cytarabine has been researched along with aclarubicin in 204 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 57 (27.94) | 18.7374 |
| 1990's | 43 (21.08) | 18.2507 |
| 2000's | 32 (15.69) | 29.6817 |
| 2010's | 59 (28.92) | 24.3611 |
| 2020's | 13 (6.37) | 2.80 |
| Authors | Studies |
|---|---|
| Fuse, Y; Katayama, Y; Kitamura, H; Kugai, N; Matsuura, Y; Motoyoshi, K; Nagata, N; Ohkawa, H; Wada, S | 1 |
| Alberto, P; Mermillod, B; Zulian, GB | 1 |
| Ashihara, E; Fujita, N; Goto, H; Inaba, T; Ito, K; Murakami, S; Okawa, K; Oku, N; Shimazaki, C; Tsuji, H | 1 |
| Abakumov, EM; Isaev, VG; Khoroshko, ND; Navashin, SM; Savchenko, VG; Sokolov, AN; Turkina, AG; Viadro, MM | 1 |
| Bergmann, OJ; Dahl, M; Ellegaard, B; Ellegaard, J | 1 |
| Horiuti, A; Kakishita, E; Kanamaru, A; Masaoka, T; Miyazaki, E; Nagai, K; Shibata, H; Takemoto, Y; Tsubaki, K; Yonezawa, T | 1 |
| Aoki, N; Goto, Y; Kanemoto, N | 1 |
| Hironaka, T; Horiike, S; Kashima, K; Misawa, S; Nakagawa, H; Nishigaki, H; Shizumi, Y; Takashima, T; Tanaka, S; Taniwaki, M | 1 |
| Bergmann, OJ | 1 |
| Boesen, AM; Brincker, H; Christensen, BE; Drivsholm, A; Ellegaard, J; Hansen, OP; Hippe, E; Jans, H; Jensen, KB; Pedersen-Bjergaard, J | 1 |
| Akazawa, K; Asano, Y; Harada, M; Morioka, E; Niho, Y; Okamura, S; Shibuya, T | 1 |
| Ausserer, B; Fink, FM; Gadner, H; Grümayer, ER; Kardos, G; Mutz, I; Revesz, T; Schuler, D; Urban, C | 1 |
| Broustet, A; Corront, B; Gastaut, JA; Maraninchi, D; Marit, G; Michallet, M; Montastruc, M; Reiffers, J; Sotto, JJ; Stoppa, AM | 1 |
| Asanaga, M; Kuriyama, K; Kusano, M; Nagai, K; Shiozawa, T | 1 |
| Chomienne, C; Degos, L; Najean, Y; Thomas, G | 1 |
| Hołowiecki, J; Mandecki, M; Wnuk-Wojnar, AM; Wojnar, J | 1 |
| Kanai, M; Kanno, M; Kobayashi, K; Kondo, K; Matano, S; Matsuda, T; Nakamura, S; Ohtake, S; Okafuji, K; Yoshida, T | 1 |
| Kyo, T; Maehama, S | 1 |
| Akahoshi, Y; Asou, N; Fujimoto, K; Fukuda, S; Ishimaru, S; Kawano, F; Murai, C; Sawatari, T; Taen, A; Takatsuki, K | 1 |
| Hassan, HT; Rees, JK | 1 |
| Bernhart, M; Fiedler, E; Kasparu, H; Krieger, O; Lutz, D; Weber, E | 1 |
| Maruyama, Y; Nagata, K; Nakamura, S; Onozawa, Y; Sakamaki, H; Yahara, Y | 1 |
| Akagi, K; Asou, N; Goto, J; Hamasaki, N; Hidaka, M; Kawano, F; Kurisaki, H; Sawatari, T; Suzushima, H; Takatsuki, K | 1 |
| Kano, Y; Kitagawa, S; Miura, Y; Muto, Y; Sakamoto, S; Sasaki, R; Suda, K; Takaku, F; Tsuboyama, A; Yoshida, M | 1 |
| Hisano, S; Ishibashi, M; Kawara, T; Kimura, N; Kyoushouin, K; Morioka, E; Okumura, M | 1 |
| Ishikawa, I; Kaneko, H; Katoh, M; Kojima, N; Shirai, T; Umeda, M; Yamaguchi, R; Yamauchi, M | 1 |
| Krc, I; Mlcochová, E; Myslivecek, M | 1 |
| Esumi, N; Fujiwara, F; Hashida, T; Ikushima, S; Imashuku, S; Ishii, T; Morioka, Y; Okano, S; Todo, S; Yoshihara, T | 1 |
| Adachi, S; Akiyama, Y; Kiriyama, Y; Kubota, Y; Mikawa, H; Takimoto, T; Tanizawa, A | 1 |
| Hatae, Y; Hatayama, Y; Nakadate, H; Takeda, T | 1 |
| Dohy, H; Kyo, T | 1 |
| Fink, FM; Gadner, H; Grümayer, ER; Kardos, G; Revesz, T; Schuler, D | 2 |
| Berthold, F; Buchmann, S; Dopfer, R; Fengler, R; Graf, N; Holldack, J; Jobke, A; Jürgens, H; Klingebiel, T; Riehm, H | 1 |
| Hirai, J; Itoh, K; Kanno, M; Kobayashi, K; Matsuda, T; Nakamura, S; Ohtake, S; Saito, Y; Tachimori, K; Yoshida, T | 1 |
| Hattori, M; Kaneko, Y; Sakurai, M; Sampi, K | 1 |
| Abe, T; Aoki, Y; Nagasawa, T; Nakazawa, M; Ninomiya, H; Shibuya, A | 1 |
| Fukutani, H; Kataoka, T; Takeyama, H; Watanabe, E; Yano, K | 1 |
| Beck, JD | 1 |
| Ishii, E; Kato, Y; Matsuzaki, A; Miyazaki, S; Ueda, K | 1 |
| Aoki, N; Imai, Y; Murohashi, I; Nara, N; Tanikawa, S; Yamashita, Y | 1 |
| Björkholm, M; Killander, A | 1 |
| Morioka, E; Niho, Y; Ohhara, N; Okamura, S; Shibuya, T; Taniguchi, S | 1 |
| Iwase, Y; Sakagami, H; Tsugaya, M; Washida, H | 1 |
| Ehninger, G; Freund, M; Heil, G; Hoelzer, D; Kurrle, E; Link, H; Mitrou, PS | 1 |
| Benavides, M; Delgado, M; Gastiaburu, J; Goldschmidt, E; Machover, D; Mathe, G; Misset, JL; Vandenbulcke, JM | 1 |
| Hibi, S; Imashuku, S; Morimoto, S; Morioka, Y; Nakajima, T; Sugimoto, T; Todo, S | 1 |
| Lutz, D | 1 |
| Yamada, K | 3 |
| Imura, H; Ino, T; Matsui, T; Nakamura, K; Okamoto, M; Ono, Y; Saito, M; Shigemura, H; Shimizu, S; Takada, T | 1 |
| Kataoka, T; Takeyama, H; Watanabe, E; Yano, K | 1 |
| Asou, N; Kawano, F; Matsuoka, Y; Tajima, H; Takatsuki, K | 1 |
| Kraemer, HP; Röthig, HJ; Sedlacek, HH | 1 |
| Kurita, S; Masaoka, T; Ogawa, N; Ota, K; Uzuka, Y; Yamada, K | 1 |
| Ito, K; Kobayashi, K; Matsuda, T; Nakagoshi, T; Nakamura, E; Nakamura, S; Nakanishi, J; Natori, K; Ohtake, S; Yoshida, T | 1 |
| Kawamura, S; Maekawa, I; Miyake, T; Sasaki, H | 1 |
| Higashidani, M; Imai, Y; Kawaguchi, K; Onozawa, Y; Yahara, Y; Yoshida, M | 1 |
| Kobayashi, M; Tahara, T | 1 |
| Hattori, M; Hayashi, Y; Honda, T; Sampi, K | 1 |
| Ishige, K; Oguro, M; Takagi, T | 1 |
| Ijima, H; Karube, T; Maehara, M; Muchi, H | 1 |
| Brincker, H; Drivsholm, A; Ellegaard, J; Freund, L; Jensen, KB; Jensen, MK; Nissen, NI; Pedersen-Bjergaard, J | 1 |
| Epstein, J; Preisler, HD | 1 |
| Hirano, M; Ino, T; Matsui, T; Morishita, Y; Nakamura, K; Ono, Y; Saito, M; Shigemura, H; Shimizu, S | 1 |
| Hamami, T; Haruyama, H; Ijichi, H; Isemura, T; Nakagawa, M; Nakajima, Y; Shimazaki, C; Ura, Y | 1 |
| Adachi, T; Hamasaki, K; Hara, M; Kimura, I; Kitajima, K; Kohi, F; Lai, M; Sanada, H; Takahashi, I; Takaoka, K; Tokioka, M; Uchida, K; Watanabe, S; Yorimitsu, S | 1 |
| Adachi, T; Endo, Y; Fujimoto, S; Hara, M; Kimura, I; Kitajima, K; Kohi, F; Lai, M; Oda, Y; Ohmoto, E; Sanada, H; Takahashi, I; Takaoka, K; Tokioka, M; Uchida, K; Watanabe, S; Yorimitsu, S | 1 |
| Ohno, R; Yamada, K | 1 |
| Kimura, K | 1 |
| Fukuda, R; Ichikawa, Y; Kawada, H; Kobayashi, N; Nagao, T; Yonekura, S | 1 |
| Aoyagi, A; Arimura, H; Furusawa, S; Koike, T; Saito, K; Sakuma, H; Tsunogake, S; Waga, K; Yamada, K; Yamato, H | 1 |
| Aoyagi, M; Enokihara, H; Koike, T; Nakamura, Y; Saito, K; Tsunogake, S; Watanabe, K; Yamada, K; Yamato, H; Yoshida, M | 1 |
| Aoyagi, A; Arimura, H; Furusawa, S; Koike, T; Noguchi, M; Saito, K; Sakuma, H; Waga, K; Yamada, K; Yamato, H | 1 |
| Arima, N; Hidaka, S; Matsumoto, T; Matsushita, K; Ohtsubo, H; Tanaka, H | 1 |
| Clausen, N; Ellegaard, J; Hokland, P; Langkjer, ST; Nørgaard, JM; Palshof, T | 1 |
| Amaki, I; Kawashima, K; Kimura, K; Maekawa, T; Masaoka, T; Nagura, E; Ohta, K; Takaku, F; Uchino, H; Yamada, K | 1 |
| Kaletin, GI; Pirogova, NA; Volkova, MA | 1 |
| Perilov, AA; Poddubnaia, IV | 1 |
| Abe, Y; Hatanaka, T; Ito, T; Kamiya, O; Nagata, K; Ohara, K; Ono, Y; Saito, M | 1 |
| Arimori, S; Fukuda, R; Ichikawa, Y; Kawada, H; Komatsuda, M; Masumoto, A; Nagao, T; Watanabe, S; Yonekura, S | 1 |
| Akashi, K; Gondo, H; Harada, M; Hayashi, S; Murakawa, M; Niho, Y; Okamura, T; Shibuya, T; Tamura, K; Teshima, T | 1 |
| Hansen, PB; Hippe, E; Johnsen, HE | 1 |
| Fujita, H; Hirayama, M; Kohgo, Y; Kura, T; Mogi, Y; Nakaya, R; Niitsu, Y; Tsuji, N; Watanabe, N | 1 |
| Hirakawa, K; Horiike, S; Kaneko, H; Kashima, K; Misawa, S; Nakai, H; Nakao, M; Taniwaki, M; Ueda, Y | 1 |
| Elonen, E; Jokipii, A; Lautenschlager, I; Lyytikäinen, O; Ruutu, P; Tiittanen, L | 1 |
| Clausen, N; Hokland, P; Langkjer, ST; Nørgaard, JM; Palshof, T; Pedersen, B | 1 |
| Saito, K | 1 |
| Harada, M; Mizuno, S; Nagafuji, H; Shibuya, T | 1 |
| Boesen, AM; de Nully Brown, P; Grønbaek, K; Hansen, OP; Hippe, E; Hoffmann, T; Jensen, MK; Pedersen-Bjergaard, J; Storm, HH; Thorling, K | 1 |
| Ezaki, K; Hirano, M; Ino, T; Kojima, H; Maruyama, F; Matsui, T; Miyazaki, H; Nomura, T; Okamoto, M; Tsuzuki, M; Yamaguchi, T | 1 |
| Hanada, R; Hongo, T; Horikoshi, Y; Sakurai, M; Yajima, S | 1 |
| Asami, K; Eguchi, H; Fujimoto, T; Gushiken, T; Hirota, T; Hyakuna, N; Imaizumi, M; Kamitamari, A; Katano, N; Kawakami, K; Koizumi, S; Komatu, K; Miyake, M; Mugishima, H; Nakadate, N; Nishikawa, K; Shirahata, A; Takitani, K; Tsurasawa, M; Yanase, T | 1 |
| Bukh, A; Clausen, N; Hokland, P; Langkjer, ST; Nørgaard, JM; Palshof, T | 1 |
| Diehl, V; Knöppel-Schwark, S; Lathan, B; Schwonzen, M; Staib, P; Steinmetz, HT; Tesch, H; Voliotis, D; Wickramanayake, PD | 1 |
| Amemiya, Y; Furukawa, Y; Hoshino, M; Imagawa, S; Izumi, T; Kawano, C; Kirito, K; Komatsu, N; Kuribara, R; Miura, Y; Miyazato, A; Muroi, K; Omine, K; Otsuki, T; Shimizu, R; Suzuki, T; Tabata, M; Takahashi, H; Takatoku, M; Terui, Y; Tomizuka, H; Toshima, M; Tsunoda, J; Uchida, M; Yoshida, M | 1 |
| Kusama, H; Matsuoka, T; Ohsaka, A; Taguchi, H; Takagi, S | 1 |
| Almqvist, A; Elonen, E; Hänninen, A; Jansson, SE; Järventie, G; Koistinen, P; Koivunen, E; Lahtinen, R; Lehtinen, M; Nousiainen, T; Pelliniemi, TT; Rajamäki, A; Remes, K; Ruutu, T; Timonen, T; Vilpo, J; Volin, L | 1 |
| Hokland, P; Kristensen, JS; Nørgaard, JM; Olesen, G; Pedersen, B | 1 |
| Aoyagi, A; Aoyagi, M; Arai, H; Arai, Y; Furusawa, S; Gunnji, H; Handa, T; Inoue, F; Kawagoe, Y; Kitsukawa, Y; Nakamura, Y; Saito, K; Tadokoro, J; Takahashi, W; Tsurumi, S; Waga, K; Yamamoto, K | 1 |
| Adachi, K; Akiyama, H; Asou, N; Hiraoka, A; Kageyama, S; Kanamaru, A; Ohno, R; Omoto, E; Tamura, J | 1 |
| Kaya, H; Maeno, K; Matsuda, T; Nakamura, S; Ohtake, S; Okafuji, K; Tanaka, N; Terasaki, Y | 1 |
| Hokland, P; Langkjer, ST; Nørgaard, JM; Palshof, T; Pedersen, B | 1 |
| Abe, T; Arai, Y; Gotoh, S; Ishikawa, T; Kakazu, N; Matsushita, A; Nagai, K; Ohki, M; Ohno, T; Shinzato, I; Takahashi, T; Tsuchiya, T | 1 |
| Aoki, S; Imai, K; Kazama, Y; Shimizu, H; Takahashi, T; Tsujisaki, M; Yoshimoto, M | 1 |
| Choi, YK; Hwang, YK; Park, YS | 1 |
| Eguchi, M; Hayashi, Y; Hibi, S; Hongo, T; Imaizumi, M; Ishii, E; Isoyama, K; Kamada, N; Kawasaki, H; Kinukawa, N; Kosaka, Y; Mizutani, S; Nishimura, S; Oda, M; Oda, T; Okamura, T; Okawa, H; Tsukimoto, I | 1 |
| Bendix, K; Hokland, P; Kjeldsen, E; Kristensen, JS; Meyer, K; Nørgaard, JM; Olesen, G; Olesen, LH; Pedersen, B | 1 |
| Björeman, M; Björkholm, M; Gahrton, G; Grimfors, G; Gruber, A; Hast, R; Killander, A; Lerner, R; Liliemark, J; Mattson, S; Oberg, G; Paul, C; Simonsson, B; Stalfelt, AM; Stenke, L; Tidefelt, U; Udén, AM | 1 |
| Arai, H; Arai, Y; Gunji, H; Handa, T; Maki, K; Mitani, K; Nakamura, F; Nakamura, Y; Saito, K; Tadokoro, J | 1 |
| Chiba, H; Hirayama, Y; Matsunaga, T; Niitsu, Y; Sagawa, T; Sakamaki, S; Takayanagi, N; Tsuji, Y | 1 |
| Meng, XL | 1 |
| Chen, FY; Hou, M; Jin, J; Li, JM; Liang, H; Qiu, XF; Qiu, ZC; Shen, Y; Shen, ZX; Song, EY; Song, YP; Wu, DP | 1 |
| Chen, ZM; Huang, J; Jiang, DZ; Jin, J; Mai, WY; Mao, LP; Meng, HT; Qian, WB; Tong, HY; Tong, Y; Wang, L; Xu, WL | 1 |
| Matsuda, K; Matsui, K; Shinohara, K; Tanaka, Y; Yamashita, K | 1 |
| Hamaki, T; Harima, A; Hoshi, K; Kajiwara, K; Kodo, H; Kozai, Y; Mizusawa, M; Yamada, K | 1 |
| Asai, O; Dobashi, N; Kobayashi, T; Osawa, H; Saito, T; Takei, Y; Usui, N; Yamaguchi, Y; Yamazaki, H; Yano, S | 1 |
| Ashida, T; Higashishiba, M; Kanamaru, A; Kawanishi, K; Mayama, T; Miyatake, J; Tatsumi, Y | 1 |
| Jiang, YQ; Li, JY; Lu, H; Qian, SX; Shen, YF; Tian, T; Wu, HX; Xu, W; Zhang, SJ | 1 |
| Ishitani, K; Kida, M; Koike, K; Kuroda, H; Matsunaga, T; Neda, H; Niitsu, Y; Nobuoka, A; Sakamaki, S; Terui, T; Watanabe, H | 1 |
| Sun, AN; Tang, XW; Wu, DP; Xue, SL | 1 |
| Chen, FP; Chen, YJ; Li, XL; Shu, YG; Wu, DS; Zhang, LQ; Zhao, XL | 1 |
| Asou, N; Hata, H; Horikawa, K; Hoshino, K; Matsuno, F; Mitsuya, H; Miyake, H; Nosaka, K; Takatsu, N; Tatetsu, H | 1 |
| Hong, M; Li, JY; Lu, H; Lu, SF; Shen, WY; Wang, LX; Yang, H; Zhang, JF | 1 |
| Huang, J; Jiang, DZ; Jin, J; Liu, H; Mai, WY; Mao, LP; Meng, HT; Qian, WB; Tong, HY; Tong, Y; Wang, L | 1 |
| Dai, L; Sun, AN; Wu, DP; Wu, YL; Xue, SL | 1 |
| Hong, M; Li, JY; Lu, H; Qian, SX; Qiu, HX; Wu, HX; Xu, W; Zhang, SJ; Zhu, BG | 1 |
| Chai, JY; Wei, N; Zheng, WQ | 1 |
| Asou, N; Eto, K; Horikawa, K; Kugimiya, MH; Mitsuya, H; Nishimura, S; Shimomura, T; Suzushima, H; Tsuda, H; Wada, N; Yamasaki, H | 1 |
| Fu, ZZ; Han, Y; He, GS; Jin, ZM; Miao, M; Qiu, HY; Sun, AN; Tang, XW; Wu, DP; Zhang, X | 1 |
| FUJIMOTO, H; HIASA, Y; HORIUCHI, N; KIMURA, S; MASUDA, K; MATSUSHITA, T; NAKAMURA, S; SHICHIJO, K; SHINOMIYA, S; TAKAHASHI, K; TAKEICHI, T; TAMAKI, Y; YAMANAKA, C | 1 |
| Imanishi, D; Imoto, S; Kanamaru, A; Kobayashi, T; Kuriyama, K; Miyazaki, Y; Morita, Y; Naoe, T; Ohnishi, K; Ohno, R; Tanimoto, M; Yagasaki, F | 1 |
| Jin, J; Qian, WB; Xu, WL | 1 |
| Chen, S; He, Y; Zhu, Y | 1 |
| Chen, S; Li, W; Qiu, H; Sun, A; Wang, Y; Wu, D | 1 |
| Huang, J; Jin, J; Mai, WY; Mao, LP; Meng, HT; Qian, JJ; Qian, WB; Song, YP; Tong, HY; Tong, Y; Xu, WL | 1 |
| Cai, Z; Chiao, JW; Huang, H; Liu, D; Ni, W; Wei, G | 1 |
| Amoh, Y; Katsuoka, K; Mukai, H; Niiyama, S; Watarai, A | 1 |
| Arai, H; Handa, T; Iso, H; Maki, K; Mitani, K; Nakamura, Y; Sasaki, K; Tadokoro, J; Takahashi, W; Tokita, K; Tsurumi, S | 1 |
| Fujita, Y; Fukushima, T; Iwao, H; Kawabata, H; Kawanami, T; Masaki, Y; Miki, M; Nakajima, A; Nakamura, T; Okazaki, T; Sakai, T; Satoh, T; Sawaki, T; Tanaka, M; Umehara, H | 1 |
| Wu, DP; Wu, ZD; Zhu, JF | 1 |
| Chang, CK; He, Q; Li, X; Song, LX; Wu, LY; Xu, L; Zhang, QX; Zhang, Y | 1 |
| Chen, L; Wei, XD; Yin, QS | 1 |
| Chen, L; Mi, R; Wei, X; Yin, Q | 1 |
| Bao, L; Huang, XJ; Jiang, B; Jiang, H; Jiang, Q; Lu, J; Qin, YZ; Zhang, XH; Zhu, HH | 1 |
| Chen, X; Gao, L; Kong, P; Li, Y; Liu, Y; Su, Y; Wang, C; Wang, Q; Wang, S; Wen, Q; Yuan, Z; Zeng, Y; Zhang, C; Zhang, X; Zhang, Y | 1 |
| Jin, J; Mai, W; Mao, L; Meng, H; Qian, J; Qian, W; Tong, H; Tong, Y; Yu, W | 1 |
| Cui, HX; Tang, XW; Wu, DP; Xue, MX; Xue, SL; Zhang, YM; Zou, JY | 1 |
| Jin, Z; Lin, G; Liu, L; Ma, A; Si, Y; Sun, Y; Wang, L; Wu, D; Zhang, X; Zhang, Y; Zhao, G | 1 |
| Chen, J; Huang, J; Jin, J; Lou, Y; Mai, W; Meng, H; Qian, W; Suo, S; Tong, H; Wei, J; Yu, W | 1 |
| Jing, Y; Liu, SY; Niu, JH; Yang, H; Yu, L; Zhang, Q; Zhu, CY; Zhu, HY | 2 |
| Cui, GX; Wu, WZ; Zhang, YP | 1 |
| Chen, S; Fu, Z; Gao, S; Han, Y; Jin, Z; Ma, X; Qiu, H; Sun, A; Tang, X; Wu, D | 1 |
| Gao, Z; Gong, R; Ma, L; Tian, W; Wang, T; Zhu, Q | 1 |
| Jiao, W; Li, X; Liu, L; Qu, Q; Wu, D; Zhang, Y | 1 |
| Chen, Y; Ding, J; Duan, L; Gu, J; Hong, M; Li, J; Li, Y; Liu, P; Lu, H; Pan, L; Qian, S; Qiu, H; Shi, J; Wang, J; Wu, H; Xu, J; Xu, Y; Yu, K; Zhang, R; Zhang, S; Zhou, J; Zhou, S; Zhu, H; Zhu, Y | 1 |
| Kakiuchi, S; Kawamoto, S; Matsuoka, H; Minami, H; Yakushijin, K; Yamamoto, K | 1 |
| Cao, XM; Chen, YX; Gu, LF; He, AL; Lei, B; Liu, J; Ma, XR; Wang, FX; Wang, J; Wang, JL; Xu, Y; Yang, Y; Zhang, PY; Zhang, WG; Zhao, WH | 1 |
| Ding, C; Jiao, W; Li, X; Liu, L; Qu, Q; Wu, D; Zhang, Y | 1 |
| Cao, YB; DA, WM; Li, SW; Li, XH; Liu, B; Liu, ZY; Wu, XX; Wu, YM; Xu, LX; Yan, B; Yang, XL | 1 |
| Tan, H; Wang, C; Xie, B; Xu, J; Yu, B; Zheng, R | 1 |
| Carter, BZ; Dai, M; Ding, B; Jiang, L; Jiang, X; Liang, S; Liu, Q; Meng, F; Wang, Z; Ye, J; Yin, C; Yu, G; Zhang, Y; Zhao, Q; Zhong, Q | 1 |
| Li, X; Liu, L; Qu, Q; Wu, D; Zhang, Y | 1 |
| Chen, SN; Fu, JH; Gao, S; Han, Y; Hu, XH; Jin, ZM; Li, Z; Qiu, HY; Sun, AN; Tang, XW; Wu, DP; Xu, Y | 1 |
| Fang-Lin, L; Hao, L; Ling-Ling, W; Lu-Qun, W; Ming, H; Xiang-Xin, L; Xue-Liang, C | 1 |
| Chen, S; Qiu, H; Shen, H; Sun, A; Sun, Y; Wu, D; Xu, Y; Yang, Z | 1 |
| Ashizawa, M; Fujiwara, S; Hatano, K; Ito, S; Kanda, Y; Kawasaki, Y; Mashima, K; Minakata, D; Muroi, K; Nakano, H; Oh, I; Ohmine, K; Okazuka, K; Sato, K; Sugimoto, M; Suzuki, T; Umino, K; Yamamoto, C; Yamasaki, R | 1 |
| Huang, XJ; Jia, JS; Jiang, H; Jiang, Q; Qin, YZ; Zhu, HH | 1 |
| Fan, C; Huang, J; Jin, J; Mai, W; Mao, L; Meng, H; Qian, W; Suo, S; Tong, H; Yu, W | 1 |
| Bao, L; Huang, XJ; Jiang, B; Jiang, H; Jiang, Q; Lu, J; Wang, J; Wen, L; Yang, SM; Zhao, T; Zhu, HH | 1 |
| Chen, JY; Dai, XB; Jiang, PJ; Ni, HW; Sun, XM; Zhang, WX | 1 |
| Gui, R; Li, M; Li, Z; Song, Y; Wei, X; Zhang, Y; Zhao, H; Zhou, J; Zu, Y | 1 |
| Fang, B; Huang, H; Lin, Q; Liu, L; Liu, Y; Song, Y; Yu, F; Zhang, Q | 1 |
| Liu, ZW; Wang, DZ; Yang, XF; Zhu, YN | 1 |
| Gomyo, H; Imoto, S; Kajimoto, K; Koizumi, T; Mizuno, I; Murayama, T; Sugimoto, T; Tobinai, K | 1 |
| Chen, Y; Hu, J; Liu, T; Yang, T; Yang, X; Zheng, J; Zheng, X; Zheng, Z | 1 |
| Cao, J; Chen, C; Chen, W; Ding, NN; Feng, H; Niu, MS; Qiu, TT; Wu, QY; Xu, KL; Zhu, HH | 1 |
| Hu, C; Jin, J; Lin, P; Lou, Y; Luo, Y; Ma, L; Mai, W; Mei, C; Meng, H; Qian, J; Qian, W; Ren, Y; Tong, H; Wei, J; Xie, L; Xu, G; Xu, W; Ye, L; Ye, X; Zhou, X | 1 |
| Ashizawa, M; Fujiwara, SI; Hatano, K; Ikeda, T; Ito, S; Kanda, Y; Kawasaki, Y; Mashima, K; Minakata, D; Morita, K; Muroi, K; Nakano, H; Oh, I; Ohmine, K; Sato, K; Sugimoto, M; Toda, Y; Umino, K; Yamamoto, C; Yamasaki, R | 1 |
| Fang, B; Fu, Y; Liu, X; Song, Y; Wei, X; Yu, F; Zhang, Y; Zhou, H; Zhou, J; Zhou, K | 1 |
| Guo, R; Han, HH; Jiang, ZX; Liu, YF; Sun, H; Wang, M | 1 |
| Hong, M; Huang, J; Li, J; Lian, Y; Qian, S; Wu, Y; Zhang, X; Zhao, H; Zhao, X; Zhu, Y | 1 |
| Chen, C; Xu, W; Yang, J | 1 |
| Cai, J; Chen, F; Li, X; Liu, J; Sheng, X; Xiao, F; Xu, L; Yin, T; Zhong, H | 1 |
| Huang, Y; Liu, DD; Lv, TT; Xu, J; Yuan, GL; Zhou, XF | 1 |
| Li, LJ; Yu, K; Zhang, JY | 1 |
| Cao, YP; Li, JG; Zhang, JL | 1 |
| Jing, Y; Li, Y; Lv, N; Wang, L; Xu, Q; Yu, L | 1 |
| Jiang, B; Sun, WX | 1 |
| Bian, Y; Huang, C; Ma, S; Ma, W; Miao, L; Miao, M; Xia, F; Yu, D | 1 |
| Jin, J; Li, J; Yu, W; Zhang, X | 1 |
| Hong, M; Li, JY; Miao, Y; Qian, SX; Qiu, HR; Sun, Q; Yang, H; Zhu, H; Zhu, Y | 1 |
| Chang, LX; Chen, X; Chen, XJ; Guo, Y; Liu, F; Liu, TF; Ruan, M; Yang, WY; Zhang, L; Zhao, BB; Zhu, XF | 1 |
| Fan, Z; Jin, Y; Li, L; Liu, W; Zhang, JY; Zhao, M; Zhou, Y | 1 |
| Cao, LH; Chen, Y; Chen, YB; Du, J; Hu, J; Hu, X; Huang, X; Jin, J; Li, X; Lou, YJ; Mao, L; Qian, JJ; Qian, WB; Tao Meng, H; Tong, H; Wang, L; Wang, Y; Wei, J; Yan Yan, X; Yang, M; You, LS; Yu, W; Zhang, SJ; Zhang, Y; Zhao, JZ; Zhu, HH | 1 |
| Han, Y; Meng, T; Qiu, H; Sun, A; Tang, X; Wang, Y; Wu, D; Xu, Y; Xue, S; Yao, Y; Zhang, Y | 1 |
| Chen, G; Fang, M; Gao, S; Gao, X; Li, X; Li, Y; Liu, H; Liu, Z; Luo, J; Ma, Y; Shen, J; Sun, K; Wang, L; Wang, X; Wei, X; Yang, L; Yu, L; Zhang, Y; Zhou, W | 1 |
| He, HS; Hua, JS; Li, F; Ma, IX; Wang, XH; Wang, XQ; Wu, M; Xie, YH; Yang, RY; Ye, XJ | 1 |
| Cao, L; Chen, SS; Hong, M; Li, JY; Qian, SX; Qiao, C; Sun, Q; Wu, WZ; Xie, Y | 1 |
| Bo, J; Dou, L; Gao, C; Gao, X; Li, H; Liu, D; Lu, N; Wang, L; Wei, Y; Wu, Y; Zhang, R; Zhu, C | 1 |
| Chang, J; Jin, J; Shen, YJ; Wang, HF; Ye, XN; Zhang, Y; Zhu, HH; Zhu, L | 1 |
| Jiang, S; Tang, Y; Zhao, L; Zhao, Y | 1 |
11 review(s) available for cytarabine and aclarubicin
| Article | Year |
|---|---|
Acute erythroleukemia with t(3;5) accompanied by hepatocellular carcinoma.
Topics: Aclarubicin; Adolescent; Adult; Aged; Anemia, Refractory, with Excess of Blasts; Carcinoma, Hepatocellular; Child; Chromosomes, Human, Pair 3; Chromosomes, Human, Pair 5; Cytarabine; Daunorubicin; Doxorubicin; Female; Hepatectomy; Hepatitis B; Humans; Leukemia, Erythroblastic, Acute; Liver Neoplasms; Male; Middle Aged; Mitomycin; Neoplasm Recurrence, Local; Neoplasms, Multiple Primary; Prednisolone; Remission Induction; Translocation, Genetic | 1991 |
[Chronic myelocytic leukemia following chemotherapy of acute promyelocytic leukemia].
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Promyelocytic, Acute; Male; Mercaptopurine; Methotrexate; Middle Aged; Prednisolone; Remission Induction | 1989 |
[Symposium on treatment of cancer. 1. Chemotherapy of acute leukemia in adults].
Topics: Aclarubicin; Acute Disease; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Clinical Trials as Topic; Cytarabine; Doxorubicin; Humans; Interferon Type I; Leukemia; Middle Aged; Naphthacenes | 1984 |
Overview of progress in hematology in 1981 with special reference to leukocyte.
Topics: Aclarubicin; Acute Disease; Adult; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Cells, Cultured; Child; Cytarabine; Deoxycytidine Monophosphate; Drug Therapy, Combination; Humans; Kinetics; Leukemia; Leukemia L1210; Leukocytes; Naphthacenes | 1982 |
[Complete remission achieved by low-dose Ara-C, aclarubicin and rhG-CSF (CAG) therapy in acute non-lymphocytic leukemia with monosomy 7 occurring after severe aplastic anemia].
Topics: Aclarubicin; Adult; Aged; Anemia, Aplastic; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 7; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Monosomy; Recombinant Proteins; Remission Induction | 1995 |
A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome.
Topics: Aclarubicin; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Treatment Outcome; Young Adult | 2011 |
Translocation t(11;19)(q23;q13.1) without MLL Rearrangement in Acute Myeloid Leukemia: Heterogeneity of the 11q23 Breakpoints.
Topics: Aclarubicin; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Breakpoints; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 19; Cytarabine; Fatal Outcome; Female; Granulocyte Colony-Stimulating Factor; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Recurrence; Translocation, Genetic | 2015 |
D-CAG (decitabine followed by cytarabine, aclarubicin, and G-CSF) for relapsed acute myeloid leukemia after hematopoietic cell transplantation.
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Combined Modality Therapy; Cytarabine; Decitabine; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Young Adult | 2016 |
[Efficacy and Safety of Decitabine Combined with CAG (Cytarabine, Aclarubicin, G-CSF) for Patients with Intermediate or High Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia: a Meta-Analysis].
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Decitabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | 2019 |
[Research Advances on Combination Strategies of Demethylating Agents for Elderly Acute Myeloid Leukemia--Review].
Topics: Aclarubicin; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute | 2019 |
Venetoclax with CAG regimen for early T-cell precursor acute lymphoblastic leukemia: a case report and literature review.
Topics: Aclarubicin; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cells, T-Lymphoid; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 2023 |
50 trial(s) available for cytarabine and aclarubicin
| Article | Year |
|---|---|
[Experience with using aclarubicin in the treatment of acute leukemia and blast crisis of chronic myeloid leukemia].
Topics: Aclarubicin; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Humans; Leukemia; Leukemia, Monocytic, Acute; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction | 1992 |
[Co-operative on salvage chemotherapy with VP-16 for malignant lymphoma. Hanshin Study Group on Treatment for Hematological Disorders].
Topics: Aclarubicin; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Female; Hodgkin Disease; Humans; Immunoblastic Lymphadenopathy; Leukemia-Lymphoma, Adult T-Cell; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Prednisolone | 1992 |
Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish national phase III trial. The Danish Society of Hematology Study Group on AML, Denmark.
Topics: Aclarubicin; Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Cytarabine; Daunorubicin; Denmark; Drug Administration Schedule; Etoposide; Humans; Leukemia, Myeloid, Acute; Middle Aged; Regression Analysis; Remission Induction; Survival Rate | 1991 |
Treatment of childhood acute nonlymphocytic leukemia: cooperative Austrian-Hungarian study AML-IGCI-84.
Topics: Aclarubicin; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Austria; Child; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Female; Humans; Hungary; Infant; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Life Tables; Male; Multicenter Studies as Topic; Prednisone; Prospective Studies; Remission Induction; Thioguanine; Vincristine | 1990 |
Treatment of acute myeloid leukemia in elderly patients: the influence of maintenance therapy (BGM 84 protocol).
Topics: Aclarubicin; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Multicenter Studies as Topic; Survival Rate | 1990 |
[Refractory anemia with partial blastosis. A new therapeutic approach].
Topics: Aclarubicin; Anemia, Refractory, with Excess of Blasts; Cholecalciferol; Clinical Trials as Topic; Colony-Stimulating Factors; Cytarabine; Granulocyte-Macrophage Colony-Stimulating Factor; Growth Substances; Humans; Interferons; Isotretinoin; Prognosis; Remission Induction | 1989 |
[Urotoxicity of enocitabine (BH-AC) and aclarubicin (ACM) in pediatric patients with hematological malignancies].
Topics: Aclarubicin; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Female; Hematuria; Humans; Infant; Leukemia; Lymphoma; Male; Multicenter Studies as Topic; Retrospective Studies | 1988 |
Aclacinomycin-A in the induction treatment of childhood acute myelogenous leukemia.
Topics: Aclarubicin; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Child; Clinical Trials as Topic; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Naphthacenes; Prospective Studies; Remission Induction | 1987 |
Aggressive combination chemotherapy of bone marrow relapse in childhood acute lymphoblastic leukemia containing aclacinomycin-A: a multicentric trial.
Topics: Aclarubicin; Adolescent; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Child; Clinical Trials as Topic; Cytarabine; Etoposide; Female; Germany, West; Humans; Leukemia, Lymphoid; Male; Naphthacenes; Prednisone; Remission Induction | 1987 |
Aclarubicin: experimental and clinical experience.
Topics: Aclarubicin; Animals; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colony-Forming Units Assay; Cytarabine; Daunorubicin; Doxorubicin; Humans; Leukemia L1210; Leukemia, Monocytic, Acute; Naphthacenes | 1985 |
[Results of follow-up studies on prognosis after immunotherapy with bestatin in acute nonlymphocytic leukemia].
Topics: Aclarubicin; Acute Disease; Adjuvants, Immunologic; Adolescent; Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Follow-Up Studies; Humans; Leucine; Leukemia; Mercaptopurine; Middle Aged; Naphthacenes; Prednisolone; Prognosis; Random Allocation | 1986 |
[New agents in the treatment of leukemia and lymphoma].
Topics: Aclarubicin; Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Clinical Trials as Topic; Cytarabine; Doxorubicin; Drug Evaluation; Humans; Infusions, Parenteral; Leukemia, Myeloid, Acute; Lymphoma; Middle Aged; Naphthacenes | 1983 |
[Symposium on treatment of cancer. 1. Chemotherapy of acute leukemia in adults].
Topics: Aclarubicin; Acute Disease; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Clinical Trials as Topic; Cytarabine; Doxorubicin; Humans; Interferon Type I; Leukemia; Middle Aged; Naphthacenes | 1984 |
[Development of new antileukemic agents].
Topics: Aclarubicin; Adolescent; Adult; Aged; Animals; Antibiotics, Antineoplastic; Clinical Trials as Topic; Cytarabine; Humans; Leukemia; Mice; Middle Aged; Naphthacenes | 1981 |
Concurrent use of granulocyte colony-stimulating factor with low-dose cytosine arabinoside and aclarubicin for previously treated acute myelogenous leukemia: a pilot study.
Topics: Aclarubicin; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Pilot Projects | 1995 |
[Comparison of low-dose cytosine arabinoside and aclarubicin in combination with granulocyte colony-stimulating factor to intermediate-dose cytosine arabinoside and mitoxantrone with or without etoposide in the treatment of relapsed acute myeloid leukemia
Topics: Aclarubicin; Adolescent; Adult; Aged; Cytarabine; Drug Administration Schedule; Drug Therapy, Combination; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Recurrence | 1995 |
Nationwide randomized comparative study of daunorubicin and aclarubicin in combination with behenoyl cytosine arabinoside, 6-mercaptopurine, and prednisolone for previously untreated acute myeloid leukemia.
Topics: Aclarubicin; Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid; Male; Mercaptopurine; Middle Aged; Prednisolone; Prospective Studies; Survival Analysis | 1994 |
[Refractory acute myelogenous leukemia successfully treated with a continuous infusion chemotherapy of low dose aclarubicin and cytosine arabinoside: a case report].
Topics: Aclarubicin; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute | 1993 |
A randomized phase II trial of low-dose aclarubicin vs very low-dose cytosine arabinoside for treatment of myelodysplastic syndromes.
Topics: Aclarubicin; Adolescent; Adult; Aged; Aged, 80 and over; Blood Component Transfusion; Cytarabine; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Probability; Survival Analysis | 1993 |
Autoimmune hypothyroidism and granulocyte-macrophage colony-stimulating factor.
Topics: Aclarubicin; Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Autoimmune Diseases; Cytarabine; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Hypothyroidism; Iodide Peroxidase; Leukemia, Myeloid; Male; Recombinant Proteins; Thyroid Function Tests; Thyrotropin; Thyroxine; Triiodothyronine | 1993 |
[Low-dose cytosine arabinoside and aclarubicin in combination with granulocyte colony-stimulating factor for the treatment of relapsed acute myeloid leukemia].
Topics: Aclarubicin; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Quality of Life; Recurrence; Remission Induction; Survival Rate | 1996 |
[Randomized controlled study of very low-dose Ara-C versus low-dose aclarubicin for the treatment of myelodysplastic syndrome].
Topics: Aclarubicin; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Cell Differentiation; Cytarabine; fas Receptor; Humans; Myelodysplastic Syndromes | 1996 |
Long-term survival and development of secondary malignancies in patients with acute myeloid leukemia treated with aclarubicin or daunorubicin plus cytosine arabinoside followed by intensive consolidation chemotherapy in a Danish national phase III trial.
Topics: Aclarubicin; Acute Disease; Adolescent; Adult; Age Factors; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Female; Follow-Up Studies; Humans; Leukemia, Myeloid; Male; Middle Aged; Neoplasms, Second Primary; Recurrence; Remission Induction; Survival Rate; Survivors | 1997 |
[Short-term intensive treatment for acute myelogenous leukemia (excluding M3 subtype) in adults].
Topics: Aclarubicin; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Humans; Leukemia, Myeloid, Acute; Mercaptopurine; Middle Aged; Mitoxantrone; Time Factors; Vinblastine; Vincristine | 1997 |
[Treatment results of intermittent and cyclic regimen with ATRA and chemotherapy in childhood acute promyelocytic leukemia. Children's Cancer and Leukemia Study Group].
Topics: Aclarubicin; Administration, Oral; Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Cytarabine; Daunorubicin; Doxorubicin; Drug Administration Schedule; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Mercaptopurine; Prednisolone; Tretinoin; Vincristine | 1997 |
Cytosine arabinoside, etoposide and aclarubicin (AVA) for the treatment of acute myeloid leukemia (AML) in elderly patients.
Topics: Aclarubicin; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Male | 1998 |
Comparison between four and eight cycles of intensive chemotherapy in adult acute myeloid leukemia: a randomized trial of the Finnish Leukemia Group.
Topics: Aclarubicin; Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prednisolone; Prospective Studies; Remission Induction; Vincristine | 1998 |
[Treatment of acute promyelocytic leukemia with all-trans retinoic acid and chemotherapy--multicenter trial of the Japan Adult Leukemia Study Group (JALSG)].
Topics: Aclarubicin; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Leukemia, Promyelocytic, Acute; Male; Mercaptopurine; Middle Aged; Mitoxantrone; Prognosis; Receptors, Retinoic Acid; Remission Induction; Retinoic Acid Receptor alpha; Tretinoin | 2000 |
Superior outcome of infant acute myeloid leukemia with intensive chemotherapy: results of the Japan Infant Leukemia Study Group.
Topics: Aclarubicin; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 11; Cytarabine; Disease-Free Survival; DNA-Binding Proteins; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Histone-Lysine N-Methyltransferase; Humans; Immunophenotyping; Infant; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Myeloid-Lymphoid Leukemia Protein; Prognosis; Proto-Oncogenes; Remission Induction; Survival Rate; Transcription Factors; Translocation, Genetic; Treatment Outcome; Vincristine | 2001 |
Long-term follow-up of patients >or=60 yr old with acute myeloid leukaemia treated with intensive chemotherapy.
Topics: Aclarubicin; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Middle Aged; Survival Rate; Thioguanine; Time Factors | 2002 |
Aclarubicin and low-dose Cytosine arabinoside in combination with granulocyte colony-stimulating factor in treating acute myeloid leukemia patients with relapsed or refractory disease and myelodysplastic syndrome: a multicenter study of 112 Chinese patien
Topics: Aclarubicin; Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Female; Granulocyte Colony-Stimulating Factor; Humans; Injections, Subcutaneous; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2005 |
Effect of low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor priming (CAG regimen) on the outcome of elderly patients with acute myeloid leukemia.
Topics: Aclarubicin; Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Treatment Outcome | 2007 |
[Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor priming in 50 patients with relapsed acute myeloid leukemia].
Topics: Aclarubicin; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Treatment Outcome; Young Adult | 2009 |
[Clinical research of modified CAG regimen for the treatment of relapsed acute myeloid leukemia].
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Treatment Outcome | 2009 |
Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor for elderly patients with previously untreated acute myeloid leukemia.
Topics: Aclarubicin; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Granulocyte Colony-Stimulating Factor; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged | 2010 |
Comparative analysis of remission induction therapy for high-risk MDS and AML progressed from MDS in the MDS200 study of Japan Adult Leukemia Study Group.
Topics: Aclarubicin; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Idarubicin; Japan; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Risk Factors; Survival Analysis; Treatment Outcome; Young Adult | 2010 |
Homoharringtonine in combination with cytarabine and aclarubicin as induction therapy improves remission and survival of patients with higher risk myelodysplastic syndromes.
Topics: Aclarubicin; Adult; Aged; Cytarabine; Drug Combinations; Female; Harringtonines; Homoharringtonine; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Treatment Outcome; Young Adult | 2010 |
Salvage chemotherapy with low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor priming in patients with refractory or relapsed acute myeloid leukemia with translocation (8;21).
Topics: Aclarubicin; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Child; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Feasibility Studies; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Salvage Therapy; Translocation, Genetic; Young Adult | 2011 |
[CAG-GO therapy for patients with relapsed or primary refractory CD33-positive acute myelogenous leukemia].
Topics: Aclarubicin; Aged; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Gemtuzumab; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Sialic Acid Binding Ig-like Lectin 3; Survival Rate | 2012 |
Clinical outcome of treatment with a combined regimen of decitabine and aclacinomycin/cytarabine for patients with refractory acute myeloid leukemia.
Topics: Aclarubicin; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Survival; Cyclin-Dependent Kinase Inhibitor p15; Cytarabine; Decitabine; DNA Methylation; DNA Modification Methylases; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Leukemia, Myeloid, Acute; Leukocytes, Mononuclear; Male; Middle Aged; Recurrence; Remission Induction; Survival Analysis; Tumor Cells, Cultured; Young Adult | 2012 |
Etoposide in combination with low-dose CAG (cytarabine, aclarubicin, G-CSF) for the treatment of relapsed or refractory acute myeloid leukemia: a multicenter, randomized control trial in southwest China.
Topics: Aclarubicin; Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; China; Cytarabine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Treatment Failure; Treatment Outcome; Young Adult | 2013 |
Homoharringtonine in combination with cytarabine and aclarubicin in the treatment of refractory/relapsed acute myeloid leukemia: a single-center experience.
Topics: Aclarubicin; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Harringtonines; Heart Diseases; Homoharringtonine; Humans; Kaplan-Meier Estimate; Kidney Diseases; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Male; Middle Aged; Recurrence; Remission Induction; Salvage Therapy; Stem Cell Transplantation; Young Adult | 2013 |
Efficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in newly diagnosed elderly patients with acute myeloid leukemia.
Topics: Aclarubicin; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Prospective Studies; Survival Analysis; Treatment Outcome | 2015 |
[Modified Shengma Biejia Decoction Combined with CAG Program for Elderly Acute Myeloid Leuke- mia Patients with Yin Deficiency Toxin Stasis Syndrome].
Topics: Aclarubicin; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drugs, Chinese Herbal; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Medicine, Chinese Traditional; Phytotherapy; Yin Deficiency | 2016 |
Thalidomide in Combination with Chemotherapy in Treating Elderly Patients with Acute Myeloid Leukemia.
Topics: Aclarubicin; Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile Neutropenia; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Outcome Assessment, Health Care; Proportional Hazards Models; Prospective Studies; Remission Induction; Thalidomide | 2018 |
Comparison of efficacy of HCAG and FLAG re-induction chemotherapy in acute myeloid leukemia patients of low- and intermediate-risk groups.
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Homoharringtonine; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Progression-Free Survival; Prospective Studies; Risk; Single-Blind Method; Treatment Failure; Vidarabine | 2019 |
Comparison of efficacy of HCAG and CAG re-induction chemotherapy in elderly low- and intermediate-risk group patients diagnosed with acute myeloid leukemia.
Topics: Aclarubicin; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Homoharringtonine; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Progression-Free Survival; Remission Induction; Retreatment; Retrospective Studies; Risk Factors; Salvage Therapy; Single-Blind Method; Time Factors; Treatment Failure | 2021 |
Chidamide, decitabine, cytarabine, aclarubicin, and granulocyte colony-stimulating factor (CDCAG) in patients with relapsed/refractory acute myeloid leukemia: a single-arm, phase 1/2 study.
Topics: Aclarubicin; Adolescent; Adult; Aminopyridines; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Decitabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Treatment Outcome; Young Adult | 2020 |
[Comparison of the Curative Efficacy of Elderly Patients with High-Risk MDS and MDS-Transformed AML between Decitabine Combined with Low-Dose CEG Regimen and Decitabine Combined with Low-Dose CAG Regimen].
Topics: Aclarubicin; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Prospective Studies; Treatment Outcome | 2020 |
A phase II study of chidamide, cytarabine, aclarubicin, granulocyte colony-stimulating factor, and donor lymphocyte infusion for relapsed acute myeloid leukemia and myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation.
Topics: Aclarubicin; Adult; Cytarabine; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Lymphocytes; Myelodysplastic Syndromes; Recurrence | 2023 |
144 other study(ies) available for cytarabine and aclarubicin
| Article | Year |
|---|---|
Parathyroid hormone-related protein as a cause of hypercalcemia in a B-cell type malignant lymphoma.
Topics: Aclarubicin; Adult; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Calcitriol; Cisplatin; Creatinine; Cyclic AMP; Cytarabine; Etoposide; Glomerular Filtration Rate; Humans; Hydroxycholecalciferols; Hydroxyproline; Hypercalcemia; Ifosfamide; L-Lactate Dehydrogenase; Lymphoma, B-Cell; Male; Osteocalcin; Parathyroid Hormone; Parathyroid Hormone-Related Protein; Prednisolone; Procarbazine; Proteins | 1992 |
ABEP as primary chemotherapy for Hodgkin's disease.
Topics: Aclarubicin; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cytarabine; Doxorubicin; Etoposide; Female; Follow-Up Studies; Hodgkin Disease; Humans; Leukemia, Myeloid, Acute; Male; Mechlorethamine; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Prednisolone; Prednisone; Procarbazine; Vincristine | 1992 |
Collection of peripheral blood stem cells mobilized by high-dose Ara-C plus VP-16 or aclarubicin followed by recombinant human granulocyte-colony stimulating factor.
Topics: Aclarubicin; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cells; Blood Component Removal; Blood Transfusion, Autologous; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Leukemia; Lymphoma; Male; Middle Aged; Recombinant Proteins | 1992 |
Gingival status during chemical plaque control with or without prior mechanical plaque removal in patients with acute myeloid leukaemia.
Topics: Aclarubicin; Acute Disease; Adolescent; Aged; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Chlorhexidine; Cytarabine; Dental Calculus; Dental Plaque; Dental Scaling; Female; Gingival Hemorrhage; Gingivitis; Humans; Leukemia, Myeloid; Leukopenia; Male; Middle Aged; Mouthwashes; Netilmicin; Piperacillin; Premedication; Thrombocytopenia | 1992 |
Electrical alternans of the T-U wave without change in the QRS complex.
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Arrhythmias, Cardiac; Cytarabine; Daunorubicin; Electrocardiography; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged | 1992 |
Alterations in oral microflora and pathogenesis of acute oral infections during remission-induction therapy in patients with acute myeloid leukaemia.
Topics: Aclarubicin; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bacteria, Aerobic; Bacteria, Anaerobic; Bacterial Infections; Candidiasis; Cytarabine; Enterobacteriaceae; Enterococcus faecalis; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mouth; Mouth Diseases; Prospective Studies; Remission Induction; Saliva | 1991 |
Drug sensitivity test for acute myeloblastic leukemia by an efficient leukemic blast colony assay using 5637-conditioned medium as a stimulator.
Topics: Aclarubicin; Adult; Aged; Aged, 80 and over; Culture Media; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Tumor Stem Cell Assay | 1990 |
[Two cases of bi-phenotypic type hybrid acute leukemia with 8;21 translocation].
Topics: Aclarubicin; Acute Disease; Aged; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Cytarabine; Female; Humans; Leukemia; Phenotype; Translocation, Genetic | 1990 |
Clinical studies on aclacinomycin A cardiotoxicity in adult patients with acute non lymphoblastic leukaemia.
Topics: Aclarubicin; Adult; Arrhythmias, Cardiac; Cytarabine; Electrocardiography; Female; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male | 1989 |
Salvage chemotherapy of refractory non-Hodgkin's lymphoma with aclacinomycin, behenoyl ara-C, etoposide, and prednisolone.
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Evaluation; Etoposide; Humans; Lymphoma, Non-Hodgkin; Neoplasm Recurrence, Local; Prednisolone; Remission Induction; Time Factors | 1989 |
[Chemotherapy of adult ANLL].
Topics: Aclarubicin; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Daunorubicin; Drug Evaluation; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Mitoxantrone; Prednisolone; Remission Induction; Survival Rate; Vincristine | 1989 |
[Relapse of gingival tumor during hematological remission in acute promyelocytic leukemia].
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Gingival Neoplasms; Humans; Leukemia, Promyelocytic, Acute; Male; Mercaptopurine; Middle Aged; Prednisolone; Recurrence; Remission Induction; Vinblastine; Vincristine | 1989 |
Low concentrations of cytosine arabinoside, 6-thioguanine, actinomycin-D and aclacinomycin A stimulates the differentiation of normal human marrow myeloid progenitor cells.
Topics: Aclarubicin; Adult; Aged; Bone Marrow; Bone Marrow Cells; Cell Differentiation; Cell Division; Cells, Cultured; Cytarabine; Dactinomycin; Female; Hematopoietic Stem Cells; Humans; Male; Middle Aged; Thioguanine | 1989 |
Preliminary results of an induction combination regimen including fractionated anthracycline.
Topics: Aclarubicin; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Evaluation; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged | 1989 |
["AB-Triple V" therapy of relapsed or refractory acute myelogenous leukemia].
Topics: Aclarubicin; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Evaluation; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Vinblastine; Vincristine; Vindesine | 1989 |
Behenoyl cytosine arabinoside, aclacinomycin A, 6-mercaptopurine, and prednisolone combination therapy for acute non-lymphocytic leukaemia in adults.
Topics: Aclarubicin; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Prednisolone | 1989 |
[A case of granulocytic sarcoma preceding acute nonlymphocytic leukemia].
Topics: Aclarubicin; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia, Myeloid; Lymph Nodes; Mercaptopurine; Prednisolone | 1989 |
[The effect of antileukemic drugs on superoxide (O2-) production by human neutrophils].
Topics: Aclarubicin; Antineoplastic Agents; Cytarabine; Dose-Response Relationship, Drug; Humans; Leukemia; Naphthacenes; Neutrophils; Superoxides | 1987 |
Combination therapy with aclacinomycin in acute leukemia.
Topics: Aclarubicin; Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Leukemia; Naphthacenes; Thioguanine | 1986 |
[Aclarubicin-related pancreatitis in a child with AML].
Topics: Aclarubicin; Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Naphthacenes; Pancreatitis; Vincristine | 1988 |
[BH-AC.AMP protocol in the treatment of refractory childhood acute leukemia].
Topics: Aclarubicin; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Drug Administration Schedule; Female; Humans; Infant; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Lymphoma; Male; Mercaptopurine; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Remission Induction | 1988 |
Treatment of acute non-lymphocytic leukemia with alternating non-cross resistant chemotherapy.
Topics: Aclarubicin; Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Resistance; Female; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Prednisolone; Prognosis; Remission Induction; Vincristine | 1988 |
[Clinical study on advanced non-Hodgkin's lymphoma with special reference to the results of chemotherapies with ACOP, ACOP-E and AclBEP regimen].
Topics: Aclarubicin; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Naphthacenes; Prednisolone; Sex Factors; Vincristine | 1987 |
Aclacinomycin A and behenoyl arabinofuranosylcytosine combination chemotherapy for previously untreated acute leukemia.
Topics: Aclarubicin; Actuarial Analysis; Acute Disease; Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Child; Child, Preschool; Cytarabine; Humans; Leukemia; Middle Aged; Naphthacenes | 1986 |
Successful treatment of acute megakaryoblastic leukaemia.
Topics: Aclarubicin; Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Naphthacenes; Thioguanine | 1986 |
[Mucosal injury of aclacinomycin A in patients with adult acute leukemia--comparison of BH-AC. AMP therapy and BH-AC. DMP therapy].
Topics: Aclarubicin; Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Hemorrhage; Humans; Leukemia; Male; Mercaptopurine; Middle Aged; Mucous Membrane; Naphthacenes; Prednisolone; Urinary Bladder Diseases | 1986 |
[Full remission of acute non-lymphatic leukemia lasting for 16 months following combination therapy with aclacinomycin A].
Topics: Aclarubicin; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Drug Administration Schedule; Etoposide; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Naphthacenes; Thioguanine | 1986 |
Treatment of juvenile chronic myelocytic leukemia with multidrug chemotherapy including aclacinomycin and N4-behenoyl-1-beta-D-arabinofuranosylcytosine.
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Cytarabine; Humans; Leukemia, Myeloid; Male; Naphthacenes | 1986 |
Effects on leukemic clonogenic cells in murine myeloid leukemia of 1-beta-D-arabinofuranosylcytosine and the anthracyclines adriamycin, daunomycin, aclacinomycin A, and 4'-epidoxorubicin.
Topics: Aclarubicin; Animals; Antibiotics, Antineoplastic; Clone Cells; Colony-Forming Units Assay; Cytarabine; Daunorubicin; Doxorubicin; Epirubicin; Kinetics; Leukemia, Myeloid, Acute; Mice; Naphthacenes | 1987 |
Daunorubicin versus aclarubicin in combination with cytarabine and thioguanine in elderly patients with acute nonlymphocytic leukemia, a preliminary report.
Topics: Aclarubicin; Acute Disease; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Humans; Leukemia; Male; Middle Aged; Naphthacenes; Thioguanine | 1987 |
Treatment of four patients with myelodysplastic syndrome with a small dose of aclacinomycin-A.
Topics: Aclarubicin; Adult; Aged; Antibiotics, Antineoplastic; Cytarabine; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Naphthacenes | 1987 |
[Our experience with combined intravesical instillation therapy of superficial bladder tumor using Aclacinomycin-A (ACM) and cytosine arabinoside (CA)].
Topics: Aclarubicin; Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cytarabine; Drug Evaluation; Female; Humans; Male; Middle Aged; Naphthacenes; Neoplasm Recurrence, Local; Remission Induction; Urinary Bladder Neoplasms | 1987 |
Age adapted induction and intensified consolidation therapy in acute myelogenous leukemia.
Topics: Aclarubicin; Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Naphthacenes; Prognosis | 1986 |
Aclacinomycin-A in the induction treatment of childhood AML.
Topics: Aclarubicin; Adolescent; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Daunorubicin; Etoposide; Female; Follow-Up Studies; Humans; Infant; Infusions, Parenteral; Leukemia, Myeloid, Acute; Male; Naphthacenes; Thioguanine | 1986 |
[Therapeutic trials of aclarubicin in previously treated acute leukemias and hematosarcomas].
Topics: Aclarubicin; Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Child; Child, Preschool; Cytarabine; Drug Evaluation; Female; Humans; Leukemia, Lymphoid; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Middle Aged; Naphthacenes | 1987 |
[Treatment of a case of childhood acute non-lymphocytic leukemia (ANLL) using high-dose cytosine arabinoside for intensification of early therapy].
Topics: Aclarubicin; Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration Schedule; Female; Humans; Leukemia; Methotrexate; Naphthacenes; Vincristine | 1987 |
[Various induction therapies in older patients with acute myeloid leukemias].
Topics: Aclarubicin; Adolescent; Adult; Aged; Aminoglutethimide; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Danazol; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Leukapheresis; Leukemia, Myeloid, Acute; Male; Middle Aged; Naphthacenes; Tamoxifen | 1985 |
Chemotherapy of acute leukemia in adults.
Topics: Aclarubicin; Acute Disease; Adult; Antineoplastic Agents; Cytarabine; Doxorubicin; Drug Evaluation; Humans; Interferon Type I; Leukemia; Naphthacenes | 1985 |
[Treatment of acute myelogenous leukemia with concurrent administration of N4-behenoyl-ara-C, aclacinomycin A, 6-mercaptopurine and prednisolone].
Topics: Aclarubicin; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Naphthacenes; Prednisolone | 1985 |
[A case of acute promyelocytic leukemia complicated with severe esophageal stenosis caused by aclacinomycin A].
Topics: Aclarubicin; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Esophageal Stenosis; Esophagoscopy; Humans; Leukemia, Lymphoid; Male; Mercaptopurine; Naphthacenes; Prednisolone | 1985 |
[Gastrointestinal symptoms of aclacinomycin A in patients with adult acute nonlymphocytic leukemia--comparison of BH-AC-DMP therapy and BH-AC-AMP therapy].
Topics: Aclarubicin; Acute Disease; Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Digestive System; Female; Gastrointestinal Diseases; Humans; Leukemia; Male; Mercaptopurine; Naphthacenes; Prednisolone | 1985 |
[ABEP chemotherapy in the treatment of advanced non-Hodgkin's lymphomas].
Topics: Aclarubicin; Adult; Aged; Alopecia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Leukopenia; Lymphoma; Male; Middle Aged; Naphthacenes; Prednisolone; Thrombocytopenia; Vincristine | 1986 |
[Comparative evaluation of combined chemotherapeutic regimens in acute non-lymphocytic leukemia].
Topics: Aclarubicin; Acute Disease; Adult; Age Factors; Ancitabine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Leukemia; Male; Mercaptopurine; Middle Aged; Naphthacenes; Prednisolone | 1983 |
[Acute pancreatitis during the treatment of BH-AC AMP regimen for acute non-lymphocytic leukemia].
Topics: Aclarubicin; Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia; Male; Mercaptopurine; Middle Aged; Naphthacenes; Pancreatitis; Prednisolone | 1984 |
[Adriamycin-aclacinomycin therapy (AA therapy) for acute leukemia unresponsive to BH-AC-DMP therapy].
Topics: Aclarubicin; Adolescent; Adult; Aged; Cytarabine; Daunorubicin; Doxorubicin; Drug Resistance; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Naphthacenes; Prednisolone | 1983 |
[Aclacinomycin A and behenoyl ara-C combination chemotherapy for untreated acute non-lymphocytic leukemia].
Topics: Aclarubicin; Acute Disease; Adolescent; Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Cytarabine; Female; Humans; Leukemia; Male; Middle Aged; Naphthacenes | 1983 |
[Combination chemotherapy of N(4)-behenoyl-1-beta-arabinofuranosylcytosine, aclarubicin, 6-MP, and prednisolone (BH-AC. AMP therapy) for adult acute non-lymphocytic leukemia].
Topics: Aclarubicin; Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Naphthacenes; Prednisolone | 1984 |
[Treatment of refractory acute lymphocytic leukemia in childhood with BH-AC, ACM, 6-MP, and prednisolone].
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Humans; Leukemia, Lymphoid; Male; Mercaptopurine; Naphthacenes; Prednisolone | 1984 |
Aclarubicin in the treatment of acute nonlymphocytic leukemia refractory to treatment with daunorubicin and cytarabine: a phase II trial.
Topics: Aclarubicin; Acute Disease; Adult; Aged; Antibiotics, Antineoplastic; Cytarabine; Daunorubicin; Drug Evaluation; Heart; Humans; Leukemia; Leukopenia; Middle Aged; Naphthacenes; Prospective Studies; Thrombocytopenia | 1984 |
A non-clonogenic assay for the determination of the sensitivity of leukemic cells to chemotherapeutic agents.
Topics: Aclarubicin; Aminoacridines; Amsacrine; Antineoplastic Agents; Bone Marrow; Cell Division; Cell Survival; Cells, Cultured; Colony-Stimulating Factors; Cytarabine; Doxorubicin; Humans; Leukemia, Myeloid, Acute; Methods; Naphthacenes; Thymidine; Tumor Stem Cell Assay | 1983 |
[Treatment of acute non-lymphocytic leukemia with concurrent administration of N4-behenoyl-beta-D-arabinofuranosylcytosine, aclacinomycin A, 6-mercaptopurine and prednisolone; a pilot study (author's transl)].
Topics: Aclarubicin; Adult; Cytarabine; Drug Therapy, Combination; Female; Humans; Leukemia; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Naphthacenes; Prednisolone | 1981 |
[Remission induction by ACM-A and BH-AC on acute promyelocytic leukemia which is resistant to DNR and CA (author's transl)].
Topics: Aclarubicin; Adult; Cytarabine; Daunorubicin; Drug Resistance; Drug Therapy, Combination; Humans; Leukemia, Myeloid, Acute; Male; Naphthacenes | 1981 |
Treatment of relapsed acute myelocytic leukemia with a combination of aclarubicin and cytosine arabinoside.
Topics: Aclarubicin; Antineoplastic Agents; Cytarabine; Drug Therapy, Combination; Humans; Leukemia, Myeloid, Acute; Naphthacenes; Recurrence | 1982 |
[Comparative evaluation of a combination of daunorubicin and cytosine arabinoside and that of aclarubicin and cytosine arabinoside in remission induction in acute non-lymphocytic leukemia].
Topics: Aclarubicin; Adult; Aged; Antibiotics, Antineoplastic; Cytarabine; Daunorubicin; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Leukemia; Leukemia, Monocytic, Acute; Leukemia, Myeloid, Acute; Male; Middle Aged; Naphthacenes; Random Allocation | 1982 |
Upregulation of cell surface expression of T-lymphoid antigens and adhesion molecules on acute myeloid leukaemia cells after in vivo administration of granulocyte colony-stimulating factor.
Topics: Aclarubicin; Acute Disease; Aged; Antigens, CD; Antigens, Surface; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Cells; Cell Adhesion Molecules; Cell Separation; Cytarabine; Female; Flow Cytometry; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid; T-Lymphocytes; Up-Regulation | 1994 |
[Successful adjuvant therapy of M-CSF with chemotherapy of two cases of chemotherapy resistant acute promyelocytic leukemia].
Topics: Aclarubicin; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Resistance; Female; Humans; Leukemia, Promyelocytic, Acute; Macrophage Colony-Stimulating Factor; Male; Mercaptopurine; Prednisolone; Remission Induction | 1995 |
Synergistic and antagonistic effects of myeloid growth factors on in vitro cellular killing by cytotoxic drugs.
Topics: Aclarubicin; Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Death; Cell Survival; Coloring Agents; Cytarabine; Daunorubicin; Drug Antagonism; Drug Screening Assays, Antitumor; Drug Synergism; Female; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interleukin-3; Leukemia, Myeloid; Male; Middle Aged; Prospective Studies; Remission Induction | 1993 |
[The comparative evaluation of the efficacy of different therapeutic plans in acute nonlymphocytic leukemias].
Topics: Aclarubicin; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Doxorubicin; Drug Evaluation; Hematopoiesis; Humans; Idarubicin; Leukemia, Myeloid, Acute; Mitoxantrone; Prednisolone; Remission Induction; Time Factors; Vincristine | 1993 |
[The current chemotherapy of acute myeloid leukemias in adults].
Topics: Aclarubicin; Acute Disease; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposide; Humans; Idarubicin; Leukemia, Myeloid; Mitoxantrone; Prognosis; Remission Induction; Time Factors | 1993 |
[Short-term intensive consolidation chemotherapy in the treatment of acute nonlymphocytic leukemia].
Topics: Aclarubicin; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Prognosis; Survival Rate; Vinblastine; Vincristine | 1994 |
[Successful treatment with combination chemotherapy of BHAC-AMP in a case of acute myelofibrosis developed from myelodysplastic syndrome with multiple chromosomal aberrations].
Topics: Aclarubicin; Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chromosome Aberrations; Cytarabine; Humans; Male; Mercaptopurine; Middle Aged; Myelodysplastic Syndromes; Prednisolone; Primary Myelofibrosis | 1993 |
Double mutations of the N-ras gene in a patient with acute myelomonocytic leukemia.
Topics: Aclarubicin; Alleles; Antineoplastic Combined Chemotherapy Protocols; Chromosome Deletion; Chromosomes, Human, Pair 12; Chromosomes, Human, Pair 9; Codon; Cytarabine; Daunorubicin; Disease Progression; Doxorubicin; Etoposide; Fatal Outcome; Genes, ras; Genetic Vectors; Humans; Karyotyping; Leukemia, Myelomonocytic, Acute; Male; Mercaptopurine; Middle Aged; Mitoxantrone; Point Mutation; Prednisolone; Vinblastine; Vincristine | 1995 |
Pneumocystis carinii pneumonia in adults with acute leukaemia: is there a need for primary chemoprophylaxis?
Topics: Aclarubicin; Acute Disease; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cohort Studies; Cyclophosphamide; Cytarabine; Daunorubicin; Dexamethasone; Etoposide; Female; Finland; Humans; Immunocompromised Host; Incidence; Leukemia; Male; Mercaptopurine; Methotrexate; Middle Aged; Mitoxantrone; Pneumonia, Pneumocystis; Prednisone; Premedication; Retrospective Studies; Thioguanine; Trimethoprim, Sulfamethoxazole Drug Combination; Vincristine | 1996 |
Relation of blast cell survival and proliferation to chemotherapy resistance in AML.
Topics: Aclarubicin; Adolescent; Adult; Aged; Antineoplastic Agents; Cell Differentiation; Cell Survival; Child; Child, Preschool; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Female; Humans; Infant; Infant, Newborn; Leukemia, Myeloid; Leukocyte Count; Male; Middle Aged; Mitoxantrone; Treatment Outcome; Tumor Cells, Cultured | 1996 |
In vitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia.
Topics: Aclarubicin; Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bleomycin; Bone Marrow; Cell Survival; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Daunorubicin; Dexamethasone; Disease-Free Survival; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Follow-Up Studies; Humans; Infant; Infant, Newborn; Life Tables; Melphalan; Methotrexate; Mitomycin; Mitoxantrone; Neoplastic Stem Cells; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Prognosis; Recurrence; Remission Induction; Tumor Cells, Cultured; Vincristine | 1997 |
MDR1 gene expression and drug resistance of AML cells.
Topics: Aclarubicin; Acute Disease; Antineoplastic Agents; Cytarabine; Daunorubicin; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Gene Expression; Genes, MDR; Humans; Lethal Dose 50; Leukemia, Myeloid; Mitoxantrone; Tumor Cells, Cultured | 1998 |
[Retrospective analysis of elderly patients > or = 60 years of age with acute leukemia].
Topics: Aclarubicin; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Daunorubicin; DNA; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Methotrexate; Middle Aged; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Retrospective Studies; Vincristine | 1998 |
Pyoderma gangrenosum following cytosine arabinoside, aclarubicin and granulocyte colony-stimulating factor combination therapy in myelodysplastic syndrome.
Topics: Aclarubicin; Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Biopsy; Cytarabine; Drug Therapy, Combination; Follow-Up Studies; Glucocorticoids; Granulocyte Colony-Stimulating Factor; Humans; Male; Myelodysplastic Syndromes; Prednisolone; Pyoderma Gangrenosum; Recurrence; Skin | 1998 |
Leukaemia cell drug resistance and prognostic factors in AML.
Topics: Aclarubicin; Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Blast Crisis; Child; Child, Preschool; Cytarabine; Cytogenetic Analysis; Daunorubicin; Drug Resistance, Neoplasm; Female; Humans; Infant; Leukemia, Myeloid; Male; Middle Aged; Multivariate Analysis; Prognosis; Tetrazolium Salts | 1999 |
Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AML) and previously untreated elderly patients with
Topics: Aclarubicin; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Lymphocyte Activation; Male; Neoplasms, Second Primary; Survival Rate; Treatment Outcome | 2000 |
Trisomy 14 with thrombocytosis and monocytosis.
Topics: Aclarubicin; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Chromosomes, Human, Pair 14; Cytarabine; Humans; Hydroxyurea; Leukemia, Myelomonocytic, Chronic; Leukocyte Disorders; Male; Monocytes; Quality of Life; Thrombocytosis; Trisomy | 2000 |
Pretreatment leukaemia cell drug resistance is correlated to clinical outcome in acute myeloid leukaemia.
Topics: Aclarubicin; Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Neoplastic Stem Cells; Prognosis; Remission Induction; Survival Analysis; Thioguanine; Treatment Outcome; Tumor Cells, Cultured | 2001 |
Involvement of the NUP98 gene in a chromosomal translocation t(11;20)(p15;q11.2) in a patient with acute monocytic leukemia (FAB-M5b).
Topics: Aclarubicin; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 20; Combined Modality Therapy; Cytarabine; Disease Progression; Fatal Outcome; Female; Hemorrhage; Humans; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Monocytic, Acute; Mercaptopurine; Middle Aged; Neoplasm Proteins; Nuclear Pore Complex Proteins; Prednisolone; Sepsis; Translocation, Genetic | 2001 |
Myelodysplastic syndrome progresses rapidly into erythroleukemia associated with synchronous double cancers of the stomach and the papilla of Vater.
Topics: Aclarubicin; Adenocarcinoma; Aged; Ampulla of Vater; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cholestasis, Extrahepatic; Chromosome Aberrations; Chromosome Disorders; Common Bile Duct Neoplasms; Cytarabine; Disease Progression; Granulocyte Colony-Stimulating Factor; Humans; Karyotyping; Leukemia, Erythroblastic, Acute; Male; Neoplasms, Multiple Primary; Neoplasms, Second Primary; Pancytopenia; Stomach Neoplasms | 2001 |
Molecular cloning and disruption of a novel gene encoding UDP-glucose: tetrahydrobiopterin alpha-glucosyltransferase in the cyanobacterium Synechococcus sp. PCC 7942.
Topics: Aclarubicin; Amino Acid Sequence; Antineoplastic Combined Chemotherapy Protocols; Bacterial Proteins; Base Sequence; Biopterins; Blotting, Southern; Blotting, Western; Cell Division; Chromatography, High Pressure Liquid; Cloning, Molecular; Cyanobacteria; Cytarabine; DNA Primers; DNA, Bacterial; Electrophoresis, Polyacrylamide Gel; Escherichia coli; Genes, Bacterial; Glucosyltransferases; Glycosylation; Molecular Sequence Data; Mutation; Polymerase Chain Reaction; Recombinant Proteins | 2001 |
FAB M4 and high CD14 surface expression is associated with high cellular resistance to Ara-C and daunorubicin: implications for clinical outcome in acute myeloid leukaemia.
Topics: Aclarubicin; Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Amsacrine; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cohort Studies; Cytarabine; Daunorubicin; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid; Leukemia, Myelomonocytic, Acute; Lipopolysaccharide Receptors; Male; Middle Aged; Mitoxantrone; Multivariate Analysis; Neoplastic Stem Cells; Thioguanine; Treatment Outcome | 2001 |
[WT1 gene expression in patients with acute myelogenous leukemia or high risk myelodysplastic syndrome successfully treated with the CAG regimen].
Topics: Aclarubicin; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; WT1 Proteins | 2002 |
[Chemotherapy with ubenimex corresponding to patient age and organ disorder for 18 cases of acute myelogeneous leukemia in elderly patients--effects, complications and long-term survival].
Topics: Aclarubicin; Age Factors; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leucine; Leukemia, Myeloid, Acute; Male; Remission Induction; Survival Rate | 2003 |
[Sensitivity of survivin-positive primary leukemia cells to chemotherapy].
Topics: Aclarubicin; Acute Disease; Adolescent; Adult; Antineoplastic Agents; Cell Survival; Cytarabine; Drug Screening Assays, Antitumor; Female; Gene Expression Regulation, Neoplastic; Humans; Inhibitor of Apoptosis Proteins; Leukemia; Male; Microtubule-Associated Proteins; Middle Aged; Neoplasm Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survivin; Tumor Cells, Cultured | 2005 |
Homoharringtonine in combination with cytarabine and aclarubicin resulted in high complete remission rate after the first induction therapy in patients with de novo acute myeloid leukemia.
Topics: Aclarubicin; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Follow-Up Studies; Harringtonines; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged | 2006 |
Acute myeloblastic leukemia in a patient with hereditary protein C deficiency.
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Enterocolitis, Pseudomembranous; Fatal Outcome; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Middle Aged; Protein C Deficiency | 2006 |
Induction of remission of relapsed acute myeloid leukemia after unrelated donor cord blood transplantation by concomitant low-dose cytarabine and calcitriol in adults.
Topics: Aclarubicin; Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Calcitriol; Cord Blood Stem Cell Transplantation; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Myeloid; Middle Aged; Recurrence; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction | 2006 |
Aclarubicin plus behenoyl cytarabine and prednisolone for previously treated acute myeloid leukemia patients.
Topics: Aclarubicin; Adolescent; Adult; Aged; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prednisolone; Salvage Therapy; Stem Cell Transplantation; Transplantation, Homologous; Treatment Outcome | 2006 |
Successful reduced-intensity stem cell transplantation in a patient with myelodysplastic syndrome combined with Sweet's syndrome.
Topics: Aclarubicin; Anemia, Refractory, with Excess of Blasts; Anti-Inflammatory Agents; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Cytarabine; Drug Therapy, Combination; Graft vs Host Disease; Humans; Male; Middle Aged; Prednisolone; Remission Induction; Sweet Syndrome; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2006 |
[Acute myelogenous leukemia with multilineage myelodysplasia, positive direct Coombs test, and elevated levels of platelet-associated IgG].
Topics: Aclarubicin; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Coombs Test; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Immunoglobulin G; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Pancytopenia; Prednisolone; Treatment Outcome | 2007 |
CAG regimen enables relapsed or refractory T-cell acute lymphocytic leukemia patients to achieve complete remission: a report of six cases.
Topics: Aclarubicin; Adolescent; Adult; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Immunophenotyping; Karyotyping; Leukemia-Lymphoma, Adult T-Cell; Male; Middle Aged; Remission Induction | 2008 |
[Therapeutic effect of priming induction regimen of CAG for newly diagnosed acute myeloid leukemia in elderly patients].
Topics: Aclarubicin; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Remission Induction | 2008 |
Treatment of therapy-related acute myeloid leukemia occurring in elderly non-Hodgkin lymphoma patients with low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor.
Topics: Aclarubicin; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Neoplasms, Second Primary | 2009 |
Successful combination therapy with infusion of allogenetic bone marrow mesenchymal stem cells and CAG regimen in hypoplastic relapsed acute myelogenous leukemia.
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Cytarabine; Female; Flow Cytometry; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Mesenchymal Stem Cell Transplantation; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Transplantation, Homologous | 2008 |
[HAA regimen as induction chemotherapy for newly diagnosed acute myelogenous leukemia].
Topics: Aclarubicin; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Harringtonines; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Treatment Outcome; Young Adult | 2008 |
[Mechanism of CAG regimen eliminating T-cell acute lymphoblastic leukemia A3 cell line].
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 2008 |
Outcomes of CAG regimen for refractory biphenotypic acute leukemia patients.
Topics: Aclarubicin; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Biphenotypic, Acute; Male; Remission Induction; Treatment Outcome; Young Adult | 2009 |
Multiple hepatocellular carcinomas developed 15 months after commencement of chemotherapy for elderly acute myelogenous leukemia.
Topics: Aclarubicin; Aged; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cytarabine; Fatal Outcome; Granulocyte Colony-Stimulating Factor; Hemochromatosis; Humans; Leukemia, Myeloid, Acute; Liver Neoplasms; Male; Neoplasms, Second Primary; Prostatic Neoplasms; Time Factors | 2009 |
[Curative effect of low dose cytarabine and aclarubin in combination with granulocyte colony-stimulating factor priming (CAG regimen) on patients with the intermediate and high-risk myelodysplastic syndrome].
Topics: Aclarubicin; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Treatment Outcome | 2010 |
[The efficacy and safety of HAA regimen as induction chemotherapy in 150 newly diagnosed acute myeloid leukemia].
Topics: Aclarubicin; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Harringtonines; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Survival Rate; Treatment Outcome; Young Adult | 2011 |
Cutaneous myeloid sarcoma presenting as grey pigmented macules.
Topics: Aclarubicin; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 7; Cytarabine; Humans; Leukemia, Myeloid, Acute; Male; Sarcoma, Myeloid; Skin; Skin Neoplasms; Skin Pigmentation; Translocation, Genetic; Treatment Outcome | 2012 |
Low-dose cytarabine plus aclarubicin for patients with previously untreated acute myeloid leukemia or high-risk myelodysplastic syndrome ineligible for standard-dose cytarabine plus anthracycline.
Topics: Aclarubicin; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes | 2012 |
[The efficacy of CAG regimen in treatment of adult patients with refractory or relapse acute lymphoblastic leukemia].
Topics: Aclarubicin; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Young Adult | 2012 |
[Comparative evaluation of CHAG and CAG priming regimen for treatment of refractory and relapsed acute myeloid leukemia].
Topics: Aclarubicin; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Glutethimide; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Treatment Outcome; Young Adult | 2012 |
CHAG priming regimen containing of cytarabine, aclacinomycin homoharringtonine and G-CSF for relapsed refractory acute myelogenous leukemia: a modified combination chemotherapeutic combination.
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Granulocyte Colony-Stimulating Factor; Harringtonines; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Treatment Outcome | 2013 |
Cytarabine, aclarubicin and granulocyte colony-stimulating factor regimen represents an effective and safe salvage regimen for patients with acute myeloid leukemia refractory to first course of induction chemotherapy.
Topics: Aclarubicin; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Salvage Therapy; Treatment Outcome; Young Adult | 2013 |
Low-dose cytarabine and aclarubicin combined with granulocyte colony-stimulating factor for the treatment of relapsed or primary refractory acute lymphocytic leukemia: a retrospective study of 25 Chinese patients.
Topics: Aclarubicin; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; China; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Drug Evaluation; Drug Resistance, Neoplasm; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Retrospective Studies; Salvage Therapy; Treatment Outcome; Young Adult | 2013 |
Increasing the dose of aclarubicin in low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) can safely and effectively treat relapsed or refractory acute myeloid leukemia.
Topics: Aclarubicin; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Treatment Outcome; Young Adult | 2014 |
Low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor priming regimen versus idarubicin plus cytarabine regimen as induction therapy for older patients with acute myeloid leukemia.
Topics: Aclarubicin; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Survival Rate | 2015 |
[Clinical efficacy of decitabine combined with modified CAG regimen for relapsed-refractory acute myeloid leukemia with AML1-ETO⁺].
Topics: Aclarubicin; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Core Binding Factor Alpha 2 Subunit; Cytarabine; Decitabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Oncogene Proteins, Fusion; Recurrence; Retrospective Studies; RUNX1 Translocation Partner 1 Protein; Treatment Outcome; Young Adult | 2014 |
[Comparison of clinical efficacy between decitabine combined with CAG regimen and CAG regimen alone in patients with intermediate to high-risk myelodysplastic syndromes].
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Disease-Free Survival; Granulocyte Colony-Stimulating Factor; Humans; Myelodysplastic Syndromes; Remission Induction; Treatment Outcome | 2014 |
[The clinical efficacy of the patients of acute myeloid leukemia and myelodysplastic syndromes treated with decitabine alone, combined with half or one couse of CAG regimen].
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | 2014 |
[The comparative study of the effects between modified FLAG and CAG on relapsed or refractory acute myeloid leukemia].
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Recurrence | 2014 |
Efficacy of low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) compared to Hyper-CVAD regimen as salvage chemotherapy in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leuk
Topics: Aclarubicin; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Rate; Vincristine; Young Adult | 2015 |
[Clinical resarch of decitabine combined with modified CAG regimen for treatment of relapsed or refractory acute myeloid leukemia].
Topics: Aclarubicin; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Retrospective Studies; Treatment Outcome; Young Adult | 2015 |
[Cohort Study on GHA and New Combined Priming Chemotherapeutic Regimens in Treatment of Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome].
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; B7-1 Antigen; Cohort Studies; Cytarabine; Doxorubicin; Granulocyte Colony-Stimulating Factor; Granulocytes; Harringtonines; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Recurrence; Thrombocytopenia | 2015 |
Increasing aclarubicin dose in low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) is efficacious as salvage chemotherapy for relapsed/refractory mixed-phenotype acute leukemia.
Topics: Aclarubicin; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisolone; Recurrence; Retrospective Studies; Salvage Therapy; Treatment Outcome; Vincristine; Young Adult | 2015 |
[Clinical Efficacy of Decitabine Combined with CAG Regimen for Myelodysplastic Syndrome-RAEB and Refractory Acute Myeloid Leukemia].
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Granulocyte Colony-Stimulating Factor; Humans; Karyotype; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Pancytopenia; Recurrence; Remission Induction; Retrospective Studies; Survival Rate; Treatment Outcome | 2015 |
The hypomethylating agent decitabine prior to chemotherapy improves the therapy efficacy in refractory/relapsed acute myeloid leukemia patients.
Topics: Aclarubicin; Adolescent; Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Line, Tumor; Cytarabine; Decitabine; Disease-Free Survival; Female; Harringtonines; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Recurrence, Local; Treatment Outcome; Young Adult | 2015 |
Increasing aclarubicin dosage of the conventional CAG (low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor) regimen is more efficacious as a salvage therapy than CAG for relapsed/refractory acute myeloid leukemia.
Topics: Aclarubicin; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Cardiomyopathies; Chemical and Drug Induced Liver Injury; Cytarabine; Dose-Response Relationship, Drug; Female; Granulocyte Colony-Stimulating Factor; Humans; Kaplan-Meier Estimate; Kidney Diseases; Leukemia, Myeloid, Acute; Male; Middle Aged; Proportional Hazards Models; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Treatment Outcome; Young Adult | 2015 |
Decitabine in the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndromes, Which Combined with Complex Karyotype Respectively.
Topics: Abnormal Karyotype; Aclarubicin; Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Child; Child, Preschool; Cytarabine; Decitabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Hematuria; Humans; Induction Chemotherapy; Infections; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Retrospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2015 |
A case of simultaneous occurrence of acute myeloid leukemia and multiple myeloma.
Topics: Aclarubicin; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Multiple Myeloma; Remission Induction | 2015 |
[Outcomes of refractory or relapsed DNMT3A + cytogenetically normal acute myeloid leukemia patients followed the therapy including decitabine combined with CAG or CAG-like regimen].
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Disease-Free Survival; DNA (Cytosine-5-)-Methyltransferases; DNA Methyltransferase 3A; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Mutation; Remission Induction; Retrospective Studies | 2015 |
A low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor priming regimen versus a daunorubicin plus cytarabine regimen as induction therapy for older patients with acute myeloid leukemia: A propensity score analysis.
Topics: Aclarubicin; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Propensity Score; Proportional Hazards Models; Retrospective Studies | 2016 |
Homoharringtonine, aclarubicin and cytarabine (HAA) regimen as the first course of induction therapy is highly effective for acute myeloid leukemia with t (8;21).
Topics: Aclarubicin; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Core Binding Factor Alpha 2 Subunit; Cytarabine; Female; Follow-Up Studies; Harringtonines; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Oncogene Proteins, Fusion; Prognosis; Real-Time Polymerase Chain Reaction; Remission Induction; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RUNX1 Translocation Partner 1 Protein; Survival Rate; Translocation, Genetic; Young Adult | 2016 |
[Efficacy of HAA regimen in the treatment of 64 patients with refractory/relapsed acute myeloid leukemia].
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Harringtonines; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Rate | 2016 |
[Comparison of efficacy and prognostic factors in elderly acute myelogenous patients with MA or CAG induction chemotherapy regimen].
Topics: Aclarubicin; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Granulocyte Colony-Stimulating Factor; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Mutation; Nucleophosmin; Prognosis; Remission Induction; Retrospective Studies; Survival Rate | 2016 |
[Efficacy analysis of CAG priming regimen combined with talidomide, interferon and interleukin 2 as the induction therapy for relapsed refractory acute myeloid leukemia].
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Interferons; Interleukin-2; Leukemia, Myeloid, Acute; Recurrence; Remission Induction; Thalidomide | 2016 |
[Treatment of relapsed and refractory acute lymphocytic leukemia by modified CAG regimen].
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence | 2016 |
[Comparison of Curative Effects of HAG and CAG Regimens for Patients with AML and Medium/High-Risk MDS].
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Examination; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Remission Induction | 2016 |
Successful Cytoreduction with CAG (cytarabine, Aclarubicin and G-CSF) Therapy in Refractory Acute Myelogenous Leukemia before Allogeneic Stem Cell Transplantation.
Topics: Aclarubicin; Adolescent; Adult; Allografts; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Peripheral Blood Stem Cell Transplantation; Remission Induction | 2001 |
The outcome and prognostic factors of 248 elderly patients with acute myeloid leukemia treated with standard-dose or low-intensity induction therapy.
Topics: Aclarubicin; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Induction Chemotherapy; L-Lactate Dehydrogenase; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Prognosis; Retrospective Studies | 2016 |
Homoharringtonine combined with aclarubicin and cytarabine synergistically induces apoptosis in t(8;21) leukemia cells and triggers caspase-3-mediated cleavage of the AML1-ETO oncoprotein.
Topics: Aclarubicin; Antineoplastic Agents; Apoptosis; Caspase 3; Cell Line, Tumor; Cell Proliferation; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 8; Core Binding Factor Alpha 2 Subunit; Cytarabine; Drug Synergism; Harringtonines; Homoharringtonine; Humans; Leukemia; Oncogene Proteins, Fusion; Proteolysis; RUNX1 Translocation Partner 1 Protein; Translocation, Genetic | 2016 |
Decitabine priming prior to low-dose chemotherapy improves patient outcomes in myelodysplastic syndromes-RAEB: a retrospective analysis vs. chemotherapy alone.
Topics: Aclarubicin; Adult; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Idarubicin; Karyotype; Male; Middle Aged; Mutation; Retrospective Studies | 2017 |
Relationship between white blood cell count elevation and clinical response after G-CSF priming chemotherapy for acute myeloid leukemia.
Topics: Aclarubicin; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Remission Induction; Retrospective Studies; Young Adult | 2017 |
Efficacy and safety of G-CSF, low-dose cytarabine and aclarubicin in combination with l-asparaginase, prednisone in the treatment of refractory or relapsed acute lymphoblastic leukemia.
Topics: Aclarubicin; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Retrospective Studies; Salvage Therapy; Treatment Outcome; Young Adult | 2017 |
[Clinical Efficacy of Low-dose Decitabine Combined with CAG Regimen in Patients with Myelodysplastic Syndrome-refractory Anemia with Excess Blasts(MDS-RAEB)].
Topics: Aclarubicin; Anemia, Refractory, with Excess of Blasts; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Granulocyte Colony-Stimulating Factor; Humans; Myelodysplastic Syndromes; Retrospective Studies; Treatment Outcome | 2017 |
Decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin is as effective as standard dose chemotherapy in the induction treatment for patients aged from 55 to 69 years old with newly diagnosed acute myeloid leukemia.
Topics: Aclarubicin; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Decitabine; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Remission Induction; Retrospective Studies; Survival Rate | 2018 |
Upregulated microRNA-146a expression induced by granulocyte colony-stimulating factor enhanced low-dosage chemotherapy response in aged acute myeloid leukemia patients.
Topics: Aclarubicin; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotaxis; Coculture Techniques; Cytarabine; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Leukemic; Granulocyte Colony-Stimulating Factor; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Male; MicroRNAs; Middle Aged; Neoplasm Proteins; NF-kappa B; Prognosis; Receptors, CXCR4; RNA Interference; RNA, Neoplasm; RNA, Small Interfering; Smad4 Protein; Stem Cell Niche; Tumor Microenvironment; Up-Regulation | 2018 |
Efficacy of common salvage chemotherapy regimens in patients with refractory or relapsed acute myeloid leukemia: A retrospective cohort study.
Topics: Aclarubicin; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cohort Studies; Cytarabine; Daunorubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Harringtonines; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome; Vidarabine; Young Adult | 2018 |
Epigenetic modifier gene mutations-positive AML patients with intermediate-risk karyotypes benefit from decitabine with CAG regimen.
Topics: Aclarubicin; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cytarabine; Decitabine; Disease-Free Survival; DNA Methylation; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Genes, Modifier; Granulocyte Colony-Stimulating Factor; Humans; Kaplan-Meier Estimate; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Prognosis; Remission Induction; Retrospective Studies; Survival Rate; Young Adult | 2020 |
A retrospective study of the correlation of in vitro chemosensitivity using ATP-TCA with patient clinical outcomes in acute myeloid leukemia.
Topics: Aclarubicin; Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Decitabine; Female; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Remission Induction; Retrospective Studies; Young Adult | 2020 |
Relapsed/refractory early T-cell precursor acute lymphoblastic leukemia was salvaged by venetoclax plus HAG regimen.
Topics: Aclarubicin; Adult; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Combined Modality Therapy; Cytarabine; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Homoharringtonine; Humans; Male; Mutation; Neoplasm Proteins; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Salvage Therapy; Sulfonamides | 2020 |
Decitabine in combination with low-dose cytarabine, aclarubicin and G-CSF tends to improve prognosis in elderly patients with high-risk AML.
Topics: Aclarubicin; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Decitabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Survival Rate; Treatment Outcome | 2020 |
[Clinical outcome of CAG regimen in 26 children with aucte myeloid leukemia].
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Remission Induction; Treatment Outcome | 2019 |
CAG regimen for refractory or relapsed adult T-cell acute lymphoblastic leukemia: A retrospective, multicenter, cohort study.
Topics: Aclarubicin; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Retrospective Studies; Young Adult | 2020 |
Salvage therapy with decitabine in combination with granulocyte colony-stimulating factor, low-dose cytarabine, and aclarubicin in patients with refractory or relapsed early T-cell precursor acute lymphoblastic leukemia.
Topics: Aclarubicin; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Decitabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Salvage Therapy; Survival Analysis | 2020 |
Efficacy and safety of decitabine combined with low-dose cytarabine, aclarubicin, and granulocyte colony-stimulating factor compared with standard therapy in acute myeloid leukemia patients with TP53 mutation.
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Decitabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Mutation; Treatment Outcome; Tumor Suppressor Protein p53 | 2020 |
CAG (cytarabine, aclarubicin and granulocyte colony-stimulating factor) regimen for core binding factor acute myeloid leukaemia with measurable residual disease.
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Core Binding Factors; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Neutropenia; Retrospective Studies; Treatment Outcome | 2023 |